Investigating a unique DNA repair issue in Ewing sarcoma
Exploiting a Novel DNA Repair Defect in Ewing Sarcoma
This study is looking at how Ewing sarcoma, a bone cancer that mainly affects teens and young adults, can be treated better by understanding why some DNA repair processes don't work properly in the cancer cells, and it hopes to find new ways to improve treatment for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11024979 on NIH RePORTER |
What this research studies
This research focuses on Ewing sarcoma, a type of bone cancer that primarily affects adolescents and young adults. It aims to understand how certain DNA repair mechanisms fail in Ewing sarcoma cells, particularly looking at a defect in Microhomology-Mediated End-Joining (MMEJ). By studying the role of specific proteins involved in DNA repair, the research seeks to identify new treatment strategies that could enhance the effectiveness of existing therapies. Patients may be involved in trials that explore these novel approaches to improve outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are adolescents and young adults diagnosed with Ewing sarcoma, particularly those with metastatic or relapsed disease.
Not a fit: Patients with other types of cancers or those who do not have Ewing sarcoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Ewing sarcoma, potentially improving survival rates for affected patients.
How similar studies have performed: Previous studies have shown promise in targeting DNA repair defects in cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: D'andrea, Alan D. — Dana-Farber Cancer Inst
- Study coordinator: D'andrea, Alan D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.